Nozologen Kft.

The ophthalmology department at Nozologen Kft. is conducting extensive studies on diabetic macular edema and diabetic retinopathy, aiming to evaluate new treatment options and reduce the burden of frequent injections.

• Comparison of novel anti‑VEGF agents with established therapies
• Assessment of dosing frequency‑response relationships
• Evaluation of long‑term visual acuity outcomes
• Exploration of gene‑based approaches to sustain retinal health

With 23 active trials and a team of six investigators, the site is focused on improving vision preservation for patients with diabetes‑related eye conditions.

Research at the clinic targets both dry age‑related macular degeneration and neovascular AMD, including the challenging geographic atrophy subtype, to discover therapies that halt disease progression and restore visual function.

• Complement pathway inhibition to slow GA lesion growth
• Intravitreal gene therapy vectors evaluated against standard care
• Novel antibody fragments combined with anti‑VEGF agents
• Long‑term safety monitoring of emerging intravitreal treatments

The program reflects the site’s commitment to advancing AMD management for the growing elderly population.

The center is assessing innovative biologics for thyroid eye disease, focusing on reducing proptosis and improving ocular comfort through targeted immune modulation.

• Subcutaneous administration of anti‑IgG4 antibodies
• Evaluation of proptosis responder rates
• Safety and tolerability profiling in chronic TED patients
• Open‑label extensions for participants who previously did not respond

These trials support Nozologen Kft.’s effort to provide new therapeutic avenues for patients with this disabling condition.

A focused program investigates rapid‑acting eye drop therapy for acquired blepharoptosis, aiming to improve eyelid function without surgery.

• Topical oxymetazoline formulation testing
• Short‑term efficacy assessment within two weeks
• Safety monitoring of ocular surface tolerance
• Patient‑reported outcome measures for visual comfort

This work adds a non‑invasive option for individuals affected by drooping eyelids at Nozologen Kft..

The site is pioneering research on advanced gene‑delivery platforms such as RGX‑314 and 4D‑150, seeking durable solutions for retinal diseases that traditionally require repeated injections.

• Single‑dose AAV vector efficacy compared with standard anti‑VEGF regimens
• Durability of visual acuity improvement over one year
• Safety and immunogenicity evaluation of viral vectors
• Impact on treatment burden for patients with neovascular AMD

By integrating cutting‑edge molecular approaches, Nozologen Kft. contributes to the next generation of ophthalmic therapies.